The FDA recorded a supplement dated 2 September 2026 to Pfizer's new drug application for abrocitinib (Cibinqo), an oral JAK1 inhibitor used for moderate-to-severe atopic dermatitis. The record does not state what the supplement concerns; it could be a labelling, manufacturing or other change.
It appears on the oncology desk because JAK inhibitors carry an FDA boxed warning that includes malignancy, among them lymphoma and lung cancer, alongside serious infection, major cardiovascular events and thrombosis. Oncologists increasingly see patients referred from dermatology and rheumatology on these drugs.
- This is a supplement to an existing application; its content is not stated and it is not a new safety signal.
- JAK inhibitors carry a boxed warning that includes malignancy, including lymphoma and lung cancer.
- Ask about JAK inhibitor use when taking a history from a patient with a new cancer diagnosis.
- Discuss with the prescribing dermatologist or rheumatologist whether to stop a JAK inhibitor after a cancer diagnosis.
Why it matters
Patients on immunomodulating drugs from other specialties increasingly reach oncology, and their drug history matters.
Don't overread it
A licence supplement is not a new indication or a new safety finding.
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for oncology, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free